Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Tap

Showing results (71-80 of 235) with videos related to

Pageof 24
Sort By:
Nature Communications|September 1, 2017
ATRX is a regulator of therapy induced senescence in human cellsMarta Kovatcheva, Will Liao, Mary E Klein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2024
Best Overall Response-Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCEJiangang Liu, David S Moura, Robin L Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2023
Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue SarcomaPatrick Schöffski, Rastislav Bahleda, Andrew J Wagner, et al.
Nature Reviews. Cancer|August 13, 2020
The epigenomics of sarcomaBenjamin A Nacev, Kevin B Jones, Andrew M Intlekofer, et al.
Journal of Geriatric Oncology|May 26, 2019
Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trialEugenie Younger, Karla Ballman, Yao Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2024
The Impact of Li-Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing RecommendationsJosephine K Dermawan, David H Abramson, Sarah Chiang, et al.
Journal of Clinical Pharmacology|March 5, 2022
Effect of Mild and Moderate Hepatic Impairment (Defined by Child-Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib PharmacokineticsHamim Zahir, Jonathan Greenberg, Ching Hsu, et al.
Cancer Research|April 8, 2017
Multinuclear NMR and MRI Reveal an Early Metabolic Response to mTOR Inhibition in SarcomaValentina Di Gialleonardo, Hannah N Aldeborgh, Vesselin Miloushev, et al.
Sarcoma|March 10, 2020
Analysis of the Chemotherapy-Free Interval following Image-Guided Ablation in Sarcoma PatientsCharles Sutton, Yachao Zhang, DaeHee Kim, et al.
The American Journal of Surgical Pathology|November 15, 2022
Histopathologic Grading Is of Prognostic Significance in Primary Angiosarcoma of Breast: Proposal of a Simplified 2-tier Grading SystemMaria G Kuba, Josephine K Dermawan, Bin Xu, et al.
Pageof 24

Showing results (71-80 of 235) with videos related to

Sort By:
Pageof 24
Nature Communications|September 1, 2017
ATRX is a regulator of therapy induced senescence in human cellsMarta Kovatcheva, Will Liao, Mary E Klein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2024
Best Overall Response-Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCEJiangang Liu, David S Moura, Robin L Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2023
Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue SarcomaPatrick Schöffski, Rastislav Bahleda, Andrew J Wagner, et al.
Nature Reviews. Cancer|August 13, 2020
The epigenomics of sarcomaBenjamin A Nacev, Kevin B Jones, Andrew M Intlekofer, et al.
Journal of Geriatric Oncology|May 26, 2019
Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trialEugenie Younger, Karla Ballman, Yao Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2024
The Impact of Li-Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing RecommendationsJosephine K Dermawan, David H Abramson, Sarah Chiang, et al.
Journal of Clinical Pharmacology|March 5, 2022
Effect of Mild and Moderate Hepatic Impairment (Defined by Child-Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib PharmacokineticsHamim Zahir, Jonathan Greenberg, Ching Hsu, et al.
Cancer Research|April 8, 2017
Multinuclear NMR and MRI Reveal an Early Metabolic Response to mTOR Inhibition in SarcomaValentina Di Gialleonardo, Hannah N Aldeborgh, Vesselin Miloushev, et al.
Sarcoma|March 10, 2020
Analysis of the Chemotherapy-Free Interval following Image-Guided Ablation in Sarcoma PatientsCharles Sutton, Yachao Zhang, DaeHee Kim, et al.
The American Journal of Surgical Pathology|November 15, 2022
Histopathologic Grading Is of Prognostic Significance in Primary Angiosarcoma of Breast: Proposal of a Simplified 2-tier Grading SystemMaria G Kuba, Josephine K Dermawan, Bin Xu, et al.
Pageof 24